Heart failure and inflammation-related biomarkers as predictors of new-onset diabetes in the general population 
Introduction
Heart failure (HF) is a complex clinical syndrome characterized by impaired circulation and systemic neurohormonal activation. Despite improvements in therapy and management its global prevalence is rising, rendering HF a serious health problem with a 5-year mortality of around 50% and a 10-year mortality of around 75% [1, 2] .
HF and diabetes mellitus (DM) have several common risk factors and shared pathophysiological mechanisms, and recent literature mounts significant evidence on the reciprocal relationship between HF and DM. The incidence of HF in patients with DM is higher than in the general population; there is approximately a 2.5 fold increased risk of contracting HF in diabetics than in healthy individuals [3] . HF is also an insulin resistant state [4, 5] and patients with HF develop type 2 DM (T2DM) more often [6] . Insulin resistance associated with HF can be localized to the myocardium (myocardial insulin resistance) or it could be generalized, affecting multiple organ systems [7] . Insulin resistance developing in HF might, however, be a reversible state: HF patients on ventricular assist device (VAD) demonstrated a significant improvement in their glycaemic parameters [8] . Therefore, our study aimed to examine whether classic HF biomarkers have a predictive value in new-onset DM, or if other domains (e.g. neuroendocrine activation, endothelial activation, fibro-inflammatory axis and renal axis) might better reflect the complex pathophysiology of HF and DM.
Methods
The PREVEND (Prevention of REnal and Vascular ENd-stage Disease) study is a prospective Dutch cohort taken from the general population of Groningen, the Netherlands between the year 1997 and 1998. An in-depth description of the PREVEND study can be found elsewhere [9] [10] [11] .
From the baseline cohort (N = 8592), patients with baseline DM (N = 331) and participants with no follow-up data or who could not be linked to a pharmacy registry (N = 289) were excluded. Patients with baseline HF (N = 19) were also excluded, generating a final total of 7953 individuals free of DM and HF with complete follow-up data for DM. The PREVEND study is in accordance with the principles charted out in the Helsinki declaration. Approval from the local medical ethical committee was obtained and informed consent was provided by all participants, including the consent to link their data with pharmacy-dispensing data.
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Procedures
Participants attended two outpatient sessions between 1997 and 1998 which constituted the baseline examination. Study subjects fasted before the visit (water or tea was allowed) and provided a first morning urine sample. Venous blood was drawn into EDTA tubes; aliquots were made and stored at\ \80°C until analysis. The biomarkers tested were high-sensitive troponin-T (hs-TnT) [12] , N-terminal pro-B-type natriuretic peptide (NT-proBNP) [13] , mid-regional pro-A-type natriuretic peptide (MR-proANP) [14] , C-terminal pro-endothelin-1 (CT-proET-1) [15] , renin [9] , aldosterone [9] , C-terminal pro-arginine vasopressin (copeptin) [16] , mid-regional pro-adrenomedullin (MR-proADM) [17] , high-sensitive C-reactive protein (hs-CRP) [18] , procalcitonin [19] , plasminogen activator inhibitor-1 (PAI-1) [20] , galectin-3 [21] , urinary albumin excretion (UAE) [22] , serum creatinine [17] and cystatin-C [17] . Details of the assays can be found in the data supplement. The first follow up session was done in 4.2 ± 0.4 years, the second follow-up in 6.5 ± 0.7 years and the final follow-up in 9.5 ± 0.8 years after the baseline examination. The total follow-up period was 11.4 ± 3.2 years.
Definitions
Incident T2DM was defined as a fasting plasma glucose ≥ 7.0 mmol/L (126 mg/dL), random sample plasma glucose ≥ 11.1 mmol/L (200 mg/dL), self-reporting of a physician diagnosis or initiation of glucose-lowering medication use retrieved from central pharmacy registry [23] . Incident HF was identified using criteria described in the HF guidelines of the European Society of Cardiology [10] . Blood pressure was measured using an automatic Dinamap XL Model 9300 series device and ten blood pressure measurements were taken during 10 min; systolic and diastolic blood pressures were calculated as the mean of the last two measurements. Hypertension was defined as systolic blood pressure N 140 mm Hg, diastolic blood pressure N 90 mm Hg or self-reported usage of antihypertensive medication. Body-mass index (kg/m 2 ) was calculated as the ratio of weight to (height) 2 . Waist-hip ratio was calculated as the ratio between minimal waist circumference and hip circumference. Hypercholesterolaemia was defined as total serum cholesterol ≥ 6.5 mmol/L (251 mg/dL) or a serum cholesterol ≥ 5.0 mmol/L (193 mg/dL) if a history of myocardial infarction (MI) was present or when lipid lowering medication was used. History of MI or cerebrovascular accident (CVA) was defined as participantreported hospitalization for ≥3 days as a result of this condition. Smoking status of the patient was determined based on self-reports. Smoking was defined as current smoking or smoking cessation within the previous year. Glomerular filtration rate was estimated using the simplified modification of diet in renal disease (sMDRD) formula [24] . UAE was given as the mean of the two consecutive 24-hour urine collections.
Statistical analysis
All statistical analyses were carried out using STATA, version 14 and a p-value b 0.05 indicates statistical significance. As the PREVEND cohort has an overrepresentation of subjects with increased UAE, a statistical correction factor was employed using a weighted Cox regression model, so that the conclusions may be extended to the general population [10, 11] . A weighing factor of 11.92 was assigned to people with UAE b 10 mg/L and a weighing factor of 1.66 to those with UAE N 10 mg/mL, based on unequal inclusion probabilities. Normally distributed data are presented as mean ± standard deviation (SD) and data that are not normally distributed are presented as median ± interquartile range (IQR). Categorical variables are presented as percentages. Skewed variables were 2-log transformed in order to facilitate interpretation, i.e. in these cases, the risk estimates should be interpreted as the relative risk if the values of variables were doubled (e.g. from 1 mg/L to 2 mg/L).
Differences between two groups for normally distributed data were tested using two sample t-test while a Wilcoxon rank-sum test was used for non-normally distributed data. Differences between categorical variables were tested using Pearson's chi-square test. To estimate incidences of DM and HF, we used the Nelson-Aalen cumulative risk estimator. Proportionality assumptions were assessed with Schoenfeld residuals and Coxproportional hazards models were fitted to the data; crude hazard ratios (HR) were evaluated to assess the univariate association of individual HF biomarkers with new-onset DM. Those variables that displayed a statistical significance in this univariable model were further analysed using three models. The first model was adjusted for age and sex and only those variables that reached significance (p b 0.1) were included in the second multivariable model, which was also adjusted for classical risk factors of DM [25] . Those biomarkers that reached a significance of p b 0.05 in the second model were included in the third model which also corrected for insulin resistance. Models that did not fulfil proportionality assumptions were also assessed with logistic regression to give odds ratio (OR). Results are summarized as HRs or ORs with 95% confidence intervals (CIs) based on standard error estimates. Interpretation of the final results was done after performing a Bonferroni type adjustment for multiple analyses, and a p value b 0.0125 (=0.05/4) was deemed significant.
Results

Clinical characteristics at baseline
The study included 7953 participants that were free from both HF and DM at baseline. Subject characteristics were divided according to the incidence of DM [see Table 1 ]. Individuals who developed DM were typically older and predominantly male (N = 59%), with a more frequent history of MI and CVA compared to those that did not develop DM. Comorbidities such as hypertension, hypercholesterolaemia, and obesity were more common in those who developed T2DM. Furthermore, they had higher triglyceride levels and insulin resistance (HOMA-IR) index, and exhibited impairment of renal function with elevated serum creatinine, increased mean 24-hour UAE and reduced eGFR. Several HF biomarkers were also significantly higher in the diabetic subgroup but stretch-related markers NT-proBNP and MRproANP, and markers of the renin-angiotension-aldosterone axis showed no significant differences between the groups.
Reciprocal relation between HF and DM
DM incidence
The incidence of new-onset DM was 5.6% during the follow up period of 11 years (N = 447/7953) as shown in [Fig. 1a ]. There was a 119% increase in the risk of developing DM in participants who developed HF; total incidence of DM in participants who developed HF was 11. 
HF incidence
The 11 
Temporal association of HF and DM
Around 0.48% of the participants (N = 38/7953) developed both DM and HF, and in this subgroup 32% developed DM after HF. The mean duration of onset of HF was 4.1 ± 2.0 years and that of DM was 6.5 ± 2.2 years; the average duration of onset of DM after HF was 2.4 ± 1.8 years. The remaining 68% developed DM before HF; the mean duration of onset of DM was 5.3 ± 2.0 years, the mean duration of onset of HF was 9.1 ± 2.3 years and the average duration of HF onset after DM was 3.8 ± 2.5 years. 
Relationship of HF biomarkers with new-onset DM
Firstly, we validated the association of "HF biomarkers" with newonset HF [26] [Supplement 4]. Then, the relationship between HF and new-onset DM was evaluated using 15 biomarkers that addressed various pathophysiological scenarios occurring in HF [ Table 2 ]. The classic HF markers, NT-proBNP and MR-proANP and markers of neuroendocrine activation, renin and aldosterone displayed no predictive value in new-onset DM.
Those biomarkers that were significantly associated with new-onset DM in the crude analyses were further analysed using three models to characterize a potentially independent association of HF biomarkers with new-onset DM. PAI-1, hs-CRP, procalcitonin, co-peptin, MR-proADM and UAE remained significantly associated with new-onset DM (p value b 0.05) in the first model after adjusting for age and sex. These biomarkers, together with those that had a p value b 0.1 in the first model i.e. hs-TnT and cystatin-C, were analysed using the second model, which was also adjusted for classical risk factors of DM, namely smoking, hypertension, waist-hip ratio and family history of DM. After multivariable adjustment only hs-CRP, procalcitonin, PAI-1 and copeptin had an independent association with new-onset DM (p b 0.05). After also adjusting for insulin resistance in the third fully- 
Discussion
We demonstrate the reciprocal relationship between HF and DM in a large cohort of the general population, with each disorder increasing the risk of development of the other. This study aimed to identify common pathophysiological pathways underlying HF and DM, and to provide a deeper insight into mechanisms by which HF can cause DM. To this end, we utilized 15 biomarkers reflecting different pathophysiological scenarios occurring in HF and evaluated their relationship with newonset DM.
Our results indicate that classic HF biomarkers (i.e. NT-proBNP, MR-proANP and hs-TnT), which significantly predict HF development, did not have any predictive value in the incidence of T2DM. On the other hand, biomarkers related to inflammation, hs-CRP, procalcitonin and PAI-1 were significantly associated with DM, even after multivariable correction and displayed a predictive utility in new-onset DM. Increasing levels of copeptin (surrogate marker of vasopressin) also increased the risk of new-onset DM; although copeptin reflects neurohormonal activation, it could also be associated with systemic inflammatory responses through indirect mechanisms involving hypertension and endothelial dysfunction [27, 28] .
DM is an established risk factor for HF and is involved in cardiac damage through various macrovascular and microvascular mechanisms, and also via direct cardiotoxic effects of hyperglyceamia and hyperinsulinaemia [29] . HF is also an independent risk factor for the development of T2DM (cardiac diabetes), however, underlying pathophysiological mechanisms are poorly characterized [4, 5] . In our study, we observed that participants who developed HF, but remained free of DM (N = 283) were also insulin-resistant, and had significantly elevated baseline serum glucose levels compared to those that did not develop HF and DM, indicating that insulin resistance and hyperglycaemia are closely associated with HF even before the clinical diagnosis of HF is established, and such individuals should therefore be more intensively screened for HF. CVA, cerebrovascular accident; BMI, body-mass index; LDL, low-density lipoprotein; HDL, high-density lipoprotein; HOMA-IR, homeostatic model assessment (estimated insulin resistance); eGFR, estimated glomerular filtration rate; UAE, urinary albumin excretion; hs-TnT, high-sensitive troponin-T; NT-proBNP, Nterminal pro-B-type natriuretic peptide; MR-proANP, mid-regional pro-A-type natriuretic peptide; MR-proADM, mid-regional pro-adrenomedullin; CTproET-1, C-terminal pro-endothelin-1; PAI-1, plasminogen activator inhibitor-1; hs-CRP, high-sensitive C-reactive protein. HF -heart failure; DM -diabetes mellitus. CI, confidence interval; HR, hazard ratio; hs-TnT, high-sensitive troponin-T; NT-proBNP, N-terminal pro-B-type natriuretic peptide; MR-proANP, mid-regional pro-A-type natriuretic peptide; CT-proET-1, C-terminal pro-endothelin-1; MR-proADM, mid-regional pro-adrenomedullin; hs-CRP, high-sensitive C-reactive protein; PAI-1, plasminogen activator inhibitor-1; UAE, urinary albumin excretion. * Hazard ratios for CT-proET-1 and creatinine are presented per unit increase. Hazard ratios for other biomarkers are presented per doubling of biomarker. Biomarkers with p-value b 0.1 in Model 1 were included for further analysis using Model 2 ǂ Adjusted for age, sex, smoking status, hypertension, waist-hip ratio and family history of diabetes mellitus. Proportional hazards were not satisfied in these models, and therefore can be interpreted as an "average effect" over time points that are observed in our dataset. Biomarkers with a p-value b0.05 in Model 2 were included for analysis in the fully adjusted Model 3. § Adjusted for all variables in multivariable model and also for insulin resistance.
Myocardial insulin resistance, especially in the scenario of HF could be dangerous. HF leads to systemic hypoxia and to maximize energy efficiency under such conditions, the failing heart shifts its metabolism from fatty acids to glucose as the major fuel [30] ; when superimposed with the myocardial insulin resistant state, utilization of glucose as an alternate energy substrate is also hampered resulting in exacerbation of the pre-existing HF. Therefore, HF patients should also be more intensively monitored for (myocardial) insulin resistance.
To the best of our knowledge, there are no prospective cohort studies that describe the temporal associations of DM and HF. This study reveals that DM can either precede or follow HF, and validates that HF is an insulin resistant state. It has been demonstrated in other studies that VAD improved insulin resistance in HF patients significantly [8] , and therefore we speculated that markers of myocardial stretch (i.e. natriuretic peptides) would be associated with T2DM as haemodynamic unloading improved glycaemic parameters. This was not the case and our results indicate that classic HF biomarkers might not be related to the pathophysiological mechanisms of new-onset DM. However, inflammation-related biomarkers significantly predict new-onset DM, this strongly suggests that an indirect "inflammatory" pathway links HF biomarkers to new-onset DM [ Fig. 2 ]. It also leads us to hypothesise that HF could cause T2DM through complex immuno-inflammatory mechanisms.
Systemic inflammation is an important risk factor for HF [31, 32] ; some risk-prediction charts already incorporate hs-CRP in HF risk estimation [33] and JUPITER study demonstrated that the excess cardiovascular risk associated with inflammation (hsCRP) is amenable to statin therapy [34] . Elevated procalcitonin levels are associated with a worse prognosis in HF patients, even in those with no evidence of infection, suggesting that co-existing systemic inflammation could be responsible for clinical deterioration of these patients [35] . Although PAI-1 is a surrogate marker of endothelial thrombo-inflammation [36, 37] , its role in HF seems to be ambiguous; elevated PAI-1 levels increase the risk of MI in individuals [38] , however, genetic inhibition of PAI-1 in murine models displays severe cardiac-specific fibrosis [39] .
Inflammatory pathways are also indicated in the pathogenesis of DM, and adipose tissue appears to be a source of various inflammatory proteins. Our study shows that elevated PAI-1 levels were strongly associated with the incidence of new-onset DM. Individuals who developed T2DM also demonstrated a significant increase in waist-hip ratio, indicating that PAI-1, DM and central obesity are closely related. This is also in line with previous studies that demonstrated a significant association between PAI-1 levels and the amount of visceral adipose tissue [40] ; overexpression of PAI-1 has also been observed in cultured adipocytes and in adipose tissue of mice and humans [41] strengthening the concept that (visceral) adipose tissue is an important source of PAI-1. Interestingly, PAI-1 KO mouse models on high-fat diet displayed a significant reduction in obesity, hyperglycaemia and hyperinsulinaemia compared to wild type mice fed on a similar diet [42] . Thus, it is highly plausible that visceral adipose tissue affects the glycaemic balance of the body through PAI-1, and that PAI-1 could be a therapeutic target in DM and obesity.
Procalcitonin, usually mentioned in the context of infection, could also be elevated in obesity-associated low-grade inflammation. Several studies have demonstrated that procalcitonin is associated with chronic low-grade inflammation, obesity and insulin resistance in the general population [19, 25] . In in-vitro experiments, adipocytes stimulated by macrophages secrete procalcitonin, and hypoperfused adipose tissue is widely considered as a non-neuroendocrine depot of procalcitonin [43, 44] .
CRP is a widely used marker of inflammation, and is secreted by hepatocytes as an acute-phase response to systemic inflammatory triggers. However, recent evidence also indicates alternative sources of CRP in chronic low-grade inflammation, e.g. adipose tissue, suggesting that CRP could have a greater role in obesity-related pathophysiologies, including metabolic syndrome [45] .
Taken together with the results from our study, common risk factors involving systemic immuno-inflammatory activation appear to play a crucial role in the etiology of both HF and DM, and visceral adipose tissue correlates strongly with the incidence of both these disorders.
Other mechanisms might also operate in HF that increase the risk of new-onset DM. Certain HF medications e.g. β-blockers and thiazide diuretics are known to increase the risk of DM in patients with hypertension [46] . However, data from the NAVIGATOR trial revealed that in patients with impaired glucose tolerance, diuretics were associated with an increased risk of DM while β-blockers and calcium channel blockers were not [47] . We should also acknowledge that, paradoxically, certain anti-inflammatory medications, e.g. statins, used in HF could contribute to the excess risk associated with new-onset DM [47, 48] . Nevertheless, this evidence has to be weighed together with the cardiovascular protection offered by these drugs, especially in patients with ischaemia, dyslipidaemia and vascular comorbidities. Finally, NSAIDs are commonly used anti-inflammatory drugs, and appear to lower glucose levels in T2DM [49] . However, they are known to increase cardiovascular risk and also HF-related hospitalizations (depending on the dosage and type of NSAID) [50] , raising concerns about their usage in patients with HF.
This study indicates that inflammation plays a key role in HF associated insulin resistance and T2DM, although mechanisms involved in the immuno-inflammatory axis appear to be complex and indirect. Existing anti-inflammatory therapies also give contrasting results in reducing the risk of new-onset DM. Further studies are needed to elucidate the inflammatory mechanisms operating in DM and HF and how antiinflammatory therapies could affect their incidence rates. Our study also underscores the necessity of developing specific cardioprotective anti-inflammatory therapies that can also reduce the incidence of new-onset DM.
Clinical perspective
DM and HF frequently coexist and this portends an unfavourable prognosis and increases mortality. Our study reinforces that HF is an independent risk factor for the development of DM. As the prevalence of CHF is increasing, the number of patients developing dysglycaemia and T2DM as a consequence of HF is expected to surge in the coming years. Effective management (anti-inflammatory) strategies to combat concurrent HF and DM need to be urgently developed to address this issue. On the other hand, inflammation-related biomarkers are significantly associated with the risk of development of both DM and HF, suggesting that complex immuno-inflammatory mechanisms might be responsible for insulin resistance and DM arising against the backdrop of HF. DM, diabetes mellitus; T2DM, type 2 diabetes mellitus; HF, heart failure.
Study strengths and limitations
Firstly, our study is a large community based cohort with a long follow-up time of 11 ± 3 years. Secondly, temporal associations between HF and DM could be characterized due to its longitudinal design. Finally, biomarkers reflecting a wide spectrum of cardiovascular pathophysiological mechanisms were utilized to evaluate their association with new-onset DM as both these diseases have several shared pathophysiological mechanisms.
We also acknowledge several limitations of our study. PREVEND cohort was enriched for increased UAE and is not an exact representation of the general population; we overcame this over-representation using a statistical correction method. The subjects included were predominantly Caucasian, therefore, extension of the results to other races might not be accurate. Detection bias should also be considered; patients who developed HF are usually screened more intensely and therefore, DM arising after HF could have been detected early. On the other hand, several patients who developed DM might not have reported to the hospital immediately, and the disease could have been undiagnosed for a long time. Long-term storage effects in the samples such as degradation and denaturation must also be taken into account. Furthermore, our study is purely observational and further experimental studies are warranted to identify the source(s) and functions of pro-inflammatory bio-markers, namely PAI-1, procalcitonin and hs-CRP.
Conclusion
HF is an insulin resistant state and can either follow or precede DM. Although there is a strong reciprocal relationship between HF and DM, classic biomarkers that predict new-onset HF do not have a predictive value in new-onset DM. However, markers of inflammation are closely associated with T2DM. The pathophysiological mechanisms by which HF causes DM is not direct; complex, indirect pathophysiological mechanisms involving inflammation are indicated. Future studies are needed to explore the inflammatory link between HF and DM.
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